JP2015504056A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015504056A5 JP2015504056A5 JP2014550354A JP2014550354A JP2015504056A5 JP 2015504056 A5 JP2015504056 A5 JP 2015504056A5 JP 2014550354 A JP2014550354 A JP 2014550354A JP 2014550354 A JP2014550354 A JP 2014550354A JP 2015504056 A5 JP2015504056 A5 JP 2015504056A5
- Authority
- JP
- Japan
- Prior art keywords
- alkylene
- phenyl
- substituted
- hydroxyacrylamide
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 35
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 32
- 125000003545 alkoxy group Chemical group 0.000 claims 25
- 125000001072 heteroaryl group Chemical group 0.000 claims 25
- 125000002947 alkylene group Chemical group 0.000 claims 23
- 125000003118 aryl group Chemical group 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 19
- -1 4-azaindolyl Chemical group 0.000 claims 18
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims 15
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 13
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 11
- 229910052736 halogen Inorganic materials 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 229940002612 prodrug Drugs 0.000 claims 8
- 239000000651 prodrug Substances 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 7
- 150000001204 N-oxides Chemical class 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 6
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 125000006747 (C2-C10) heterocycloalkyl group Chemical group 0.000 claims 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 4
- 208000035690 Familial cold urticaria Diseases 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims 4
- 206010064570 familial cold autoinflammatory syndrome Diseases 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 239000002207 metabolite Substances 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 201000003076 Angiosarcoma Diseases 0.000 claims 3
- 208000022715 Autoinflammatory syndrome Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000004450 alkenylene group Chemical group 0.000 claims 3
- 125000004419 alkynylene group Chemical group 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 125000004474 heteroalkylene group Chemical group 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- FQCQGOZEWWPOKI-UHFFFAOYSA-K trisalicylate-choline Chemical compound [Mg+2].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O FQCQGOZEWWPOKI-UHFFFAOYSA-K 0.000 claims 3
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 claims 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 2
- 206010053776 Eosinophilic cellulitis Diseases 0.000 claims 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 2
- 102000003996 Interferon-beta Human genes 0.000 claims 2
- 108090000467 Interferon-beta Proteins 0.000 claims 2
- 102000003777 Interleukin-1 beta Human genes 0.000 claims 2
- 108090000193 Interleukin-1 beta Proteins 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 claims 2
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims 2
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 206010041591 Spinal osteoarthritis Diseases 0.000 claims 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- 208000008526 Wells syndrome Diseases 0.000 claims 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims 2
- 108700025316 aldesleukin Proteins 0.000 claims 2
- 229960005310 aldesleukin Drugs 0.000 claims 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 229960000590 celecoxib Drugs 0.000 claims 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- 229960000684 cytarabine Drugs 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229960001904 epirubicin Drugs 0.000 claims 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- 229960001388 interferon-beta Drugs 0.000 claims 2
- 229910052740 iodine Inorganic materials 0.000 claims 2
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229960003803 meclofenamic acid Drugs 0.000 claims 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 2
- 229960001428 mercaptopurine Drugs 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- 229960004857 mitomycin Drugs 0.000 claims 2
- 208000029974 neurofibrosarcoma Diseases 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 208000002574 reactive arthritis Diseases 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- 229960002530 sargramostim Drugs 0.000 claims 2
- 108010038379 sargramostim Proteins 0.000 claims 2
- 208000005801 spondylosis Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- JNELGWHKGNBSMD-UHFFFAOYSA-N xanthone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3OC2=C1 JNELGWHKGNBSMD-UHFFFAOYSA-N 0.000 claims 2
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims 2
- 229960004276 zoledronic acid Drugs 0.000 claims 2
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 claims 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 claims 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 1
- DSXCPDLBPYNUAY-QHHAFSJGSA-N (e)-3-[2-(3,4-dichlorophenoxy)-4-(2-morpholin-4-ylethoxy)phenyl]-n-hydroxyprop-2-enamide Chemical compound C1=C(OC=2C=C(Cl)C(Cl)=CC=2)C(/C=C/C(=O)NO)=CC=C1OCCN1CCOCC1 DSXCPDLBPYNUAY-QHHAFSJGSA-N 0.000 claims 1
- OMVSPJZGSTWRTM-XBXARRHUSA-N (e)-3-[2-(3,4-dichlorophenoxy)-4-(pyridin-3-ylmethoxy)phenyl]-n-hydroxyprop-2-enamide Chemical compound C1=C(OC=2C=C(Cl)C(Cl)=CC=2)C(/C=C/C(=O)NO)=CC=C1OCC1=CC=CN=C1 OMVSPJZGSTWRTM-XBXARRHUSA-N 0.000 claims 1
- ALPHDELDVVUZCP-FPYGCLRLSA-N (e)-3-[2-(3,4-dichlorophenoxy)-5-(pyridin-3-ylmethylamino)phenyl]-n-hydroxyprop-2-enamide Chemical compound C=1C=C(OC=2C=C(Cl)C(Cl)=CC=2)C(/C=C/C(=O)NO)=CC=1NCC1=CC=CN=C1 ALPHDELDVVUZCP-FPYGCLRLSA-N 0.000 claims 1
- XYPHIQGDDSETJZ-VMPITWQZSA-N (e)-3-[2-(3,4-dichlorophenoxy)phenyl]-n-hydroxyprop-2-enamide Chemical compound ONC(=O)\C=C\C1=CC=CC=C1OC1=CC=C(Cl)C(Cl)=C1 XYPHIQGDDSETJZ-VMPITWQZSA-N 0.000 claims 1
- FSTBOTRXBQEFCS-VQHVLOKHSA-N (e)-3-[2-(3-chlorophenoxy)-4-[2-(dimethylamino)ethoxy]phenyl]-n-hydroxyprop-2-enamide Chemical compound CN(C)CCOC1=CC=C(\C=C\C(=O)NO)C(OC=2C=C(Cl)C=CC=2)=C1 FSTBOTRXBQEFCS-VQHVLOKHSA-N 0.000 claims 1
- CLWFPGAETHMJJF-VMPITWQZSA-N (e)-3-[2-(3-chlorophenoxy)-5-(methanesulfonamido)phenyl]-n-hydroxyprop-2-enamide Chemical compound ONC(=O)/C=C/C1=CC(NS(=O)(=O)C)=CC=C1OC1=CC=CC(Cl)=C1 CLWFPGAETHMJJF-VMPITWQZSA-N 0.000 claims 1
- UKJIYIBVTVLYAQ-JXMROGBWSA-N (e)-3-[2-(3-chlorophenoxy)-5-(pyridin-2-ylmethylamino)phenyl]-n-hydroxyprop-2-enamide Chemical compound C=1C=C(OC=2C=C(Cl)C=CC=2)C(/C=C/C(=O)NO)=CC=1NCC1=CC=CC=N1 UKJIYIBVTVLYAQ-JXMROGBWSA-N 0.000 claims 1
- AOJQINUSCFRRJL-CMDGGOBGSA-N (e)-3-[2-(3-chlorophenoxy)phenyl]-n-hydroxyprop-2-enamide Chemical compound ONC(=O)\C=C\C1=CC=CC=C1OC1=CC=CC(Cl)=C1 AOJQINUSCFRRJL-CMDGGOBGSA-N 0.000 claims 1
- QSSOAUVXZWRGHO-SOFGYWHQSA-N (e)-3-[2-(3-fluorophenoxy)-4-(2-methoxyethoxy)phenyl]-n-hydroxyprop-2-enamide Chemical compound COCCOC1=CC=C(\C=C\C(=O)NO)C(OC=2C=C(F)C=CC=2)=C1 QSSOAUVXZWRGHO-SOFGYWHQSA-N 0.000 claims 1
- JTQGIBCNDPGHGU-SOFGYWHQSA-N (e)-3-[2-(3-fluorophenoxy)-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-n-hydroxyprop-2-enamide Chemical compound C1CN(C)CCN1CCOC1=CC=C(\C=C\C(=O)NO)C(OC=2C=C(F)C=CC=2)=C1 JTQGIBCNDPGHGU-SOFGYWHQSA-N 0.000 claims 1
- AVTHBIVGTKIHMK-RMKNXTFCSA-N (e)-3-[2-(3-fluorophenoxy)-5-(pyridin-3-ylmethylamino)phenyl]-n-hydroxyprop-2-enamide Chemical compound C=1C=C(OC=2C=C(F)C=CC=2)C(/C=C/C(=O)NO)=CC=1NCC1=CC=CN=C1 AVTHBIVGTKIHMK-RMKNXTFCSA-N 0.000 claims 1
- SCBCPPOKKGYKDP-CMDGGOBGSA-N (e)-3-[2-(3-fluorophenoxy)phenyl]-n-hydroxyprop-2-enamide Chemical compound ONC(=O)\C=C\C1=CC=CC=C1OC1=CC=CC(F)=C1 SCBCPPOKKGYKDP-CMDGGOBGSA-N 0.000 claims 1
- XHHVUIHTBWTZHG-BJMVGYQFSA-N (e)-3-[2-(4-chlorophenoxy)phenyl]-n-hydroxyprop-2-enamide Chemical compound ONC(=O)\C=C\C1=CC=CC=C1OC1=CC=C(Cl)C=C1 XHHVUIHTBWTZHG-BJMVGYQFSA-N 0.000 claims 1
- ZLFLPDAQTACWLH-YCRREMRBSA-N (e)-3-[2-(4-fluorophenoxy)-4-(2-methoxyethoxy)phenyl]-n-hydroxyprop-2-enamide Chemical compound COCCOC1=CC=C(\C=C\C(=O)NO)C(OC=2C=CC(F)=CC=2)=C1 ZLFLPDAQTACWLH-YCRREMRBSA-N 0.000 claims 1
- ZBJHKGSCVYLCNC-ONNFQVAWSA-N (e)-3-[2-(4-fluorophenoxy)-4-(pyridin-3-ylmethoxy)phenyl]-n-hydroxyprop-2-enamide Chemical compound C1=C(OC=2C=CC(F)=CC=2)C(/C=C/C(=O)NO)=CC=C1OCC1=CC=CN=C1 ZBJHKGSCVYLCNC-ONNFQVAWSA-N 0.000 claims 1
- KBNIOIDOXAORRG-YCRREMRBSA-N (e)-3-[2-(4-fluorophenoxy)-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-n-hydroxyprop-2-enamide Chemical compound C1CN(C)CCN1CCOC1=CC=C(\C=C\C(=O)NO)C(OC=2C=CC(F)=CC=2)=C1 KBNIOIDOXAORRG-YCRREMRBSA-N 0.000 claims 1
- GSNMYMBYJKOKIQ-XNWCZRBMSA-N (e)-3-[2-(4-fluorophenoxy)-5-(methanesulfonamido)phenyl]-n-hydroxyprop-2-enamide Chemical compound ONC(=O)/C=C/C1=CC(NS(=O)(=O)C)=CC=C1OC1=CC=C(F)C=C1 GSNMYMBYJKOKIQ-XNWCZRBMSA-N 0.000 claims 1
- WFRNYEYSFXJVNM-NYYWCZLTSA-N (e)-3-[2-(4-fluorophenoxy)-5-(pyridin-2-ylmethylamino)phenyl]-n-hydroxyprop-2-enamide Chemical compound C=1C=C(OC=2C=CC(F)=CC=2)C(/C=C/C(=O)NO)=CC=1NCC1=CC=CC=N1 WFRNYEYSFXJVNM-NYYWCZLTSA-N 0.000 claims 1
- BODKSEFVPHKXRG-XCVCLJGOSA-N (e)-3-[2-(4-fluorophenoxy)-5-(pyridin-3-ylmethylamino)phenyl]-n-hydroxyprop-2-enamide Chemical compound C=1C=C(OC=2C=CC(F)=CC=2)C(/C=C/C(=O)NO)=CC=1NCC1=CC=CN=C1 BODKSEFVPHKXRG-XCVCLJGOSA-N 0.000 claims 1
- NMTDBKDNGYDIDJ-BJMVGYQFSA-N (e)-3-[2-(4-fluorophenoxy)phenyl]-n-hydroxyprop-2-enamide Chemical compound ONC(=O)\C=C\C1=CC=CC=C1OC1=CC=C(F)C=C1 NMTDBKDNGYDIDJ-BJMVGYQFSA-N 0.000 claims 1
- HDTUYKBQZSXJDF-BOLDSZDNSA-N (e)-3-[2-[(3r)-1-(furan-2-carbonyl)piperidin-3-yl]oxyphenyl]-n-hydroxyprop-2-enamide Chemical compound ONC(=O)\C=C\C1=CC=CC=C1O[C@H]1CN(C(=O)C=2OC=CC=2)CCC1 HDTUYKBQZSXJDF-BOLDSZDNSA-N 0.000 claims 1
- XJEHJACONRPJAQ-MYSGNRETSA-N (e)-3-[2-[(3r)-1-acetylpiperidin-3-yl]oxyphenyl]-n-hydroxyprop-2-enamide Chemical compound C1N(C(=O)C)CCC[C@H]1OC1=CC=CC=C1\C=C\C(=O)NO XJEHJACONRPJAQ-MYSGNRETSA-N 0.000 claims 1
- GXTQRHMYGMZKBA-QFQMRYFISA-N (e)-3-[2-[(3r)-1-benzoylpiperidin-3-yl]oxyphenyl]-n-hydroxyprop-2-enamide Chemical compound ONC(=O)\C=C\C1=CC=CC=C1O[C@H]1CN(C(=O)C=2C=CC=CC=2)CCC1 GXTQRHMYGMZKBA-QFQMRYFISA-N 0.000 claims 1
- HDTUYKBQZSXJDF-FEAKQIBJSA-N (e)-3-[2-[(3s)-1-(furan-2-carbonyl)piperidin-3-yl]oxyphenyl]-n-hydroxyprop-2-enamide Chemical compound ONC(=O)\C=C\C1=CC=CC=C1O[C@@H]1CN(C(=O)C=2OC=CC=2)CCC1 HDTUYKBQZSXJDF-FEAKQIBJSA-N 0.000 claims 1
- XJEHJACONRPJAQ-VFNNOXKTSA-N (e)-3-[2-[(3s)-1-acetylpiperidin-3-yl]oxyphenyl]-n-hydroxyprop-2-enamide Chemical compound C1N(C(=O)C)CCC[C@@H]1OC1=CC=CC=C1\C=C\C(=O)NO XJEHJACONRPJAQ-VFNNOXKTSA-N 0.000 claims 1
- GXTQRHMYGMZKBA-HHNLSAEISA-N (e)-3-[2-[(3s)-1-benzoylpiperidin-3-yl]oxyphenyl]-n-hydroxyprop-2-enamide Chemical compound ONC(=O)\C=C\C1=CC=CC=C1O[C@@H]1CN(C(=O)C=2C=CC=CC=2)CCC1 GXTQRHMYGMZKBA-HHNLSAEISA-N 0.000 claims 1
- IAOBSYABBAORPN-XVNBXDOJSA-N (e)-3-[4-(2-acetamidoethoxy)-2-(3,4-dichlorophenoxy)phenyl]-n-hydroxyprop-2-enamide Chemical compound CC(=O)NCCOC1=CC=C(\C=C\C(=O)NO)C(OC=2C=C(Cl)C(Cl)=CC=2)=C1 IAOBSYABBAORPN-XVNBXDOJSA-N 0.000 claims 1
- LECVZVZCTPWMHJ-SOFGYWHQSA-N (e)-3-[4-(2-acetamidoethoxy)-2-(3-chlorophenoxy)phenyl]-n-hydroxyprop-2-enamide Chemical compound CC(=O)NCCOC1=CC=C(\C=C\C(=O)NO)C(OC=2C=C(Cl)C=CC=2)=C1 LECVZVZCTPWMHJ-SOFGYWHQSA-N 0.000 claims 1
- CZTAHSCPXJMCJC-YCRREMRBSA-N (e)-3-[4-(2-acetamidoethoxy)-2-(4-fluorophenoxy)phenyl]-n-hydroxyprop-2-enamide Chemical compound CC(=O)NCCOC1=CC=C(\C=C\C(=O)NO)C(OC=2C=CC(F)=CC=2)=C1 CZTAHSCPXJMCJC-YCRREMRBSA-N 0.000 claims 1
- KEQZMROYUOXYTO-VQHVLOKHSA-N (e)-3-[4-[2-(dimethylamino)ethoxy]-2-(3-fluorophenoxy)phenyl]-n-hydroxyprop-2-enamide Chemical compound CN(C)CCOC1=CC=C(\C=C\C(=O)NO)C(OC=2C=C(F)C=CC=2)=C1 KEQZMROYUOXYTO-VQHVLOKHSA-N 0.000 claims 1
- NQMHUZYAISCFMF-VMPITWQZSA-N (e)-3-[5-acetamido-2-(3-chlorophenoxy)phenyl]-n-hydroxyprop-2-enamide Chemical compound ONC(=O)/C=C/C1=CC(NC(=O)C)=CC=C1OC1=CC=CC(Cl)=C1 NQMHUZYAISCFMF-VMPITWQZSA-N 0.000 claims 1
- NBQOHBXQBXXUHV-VMPITWQZSA-N (e)-3-[5-acetamido-2-(3-fluorophenoxy)phenyl]-n-hydroxyprop-2-enamide Chemical compound ONC(=O)/C=C/C1=CC(NC(=O)C)=CC=C1OC1=CC=CC(F)=C1 NBQOHBXQBXXUHV-VMPITWQZSA-N 0.000 claims 1
- QLWNLVSIVRJGPY-XNWCZRBMSA-N (e)-3-[5-acetamido-2-(4-fluorophenoxy)phenyl]-n-hydroxyprop-2-enamide Chemical compound ONC(=O)/C=C/C1=CC(NC(=O)C)=CC=C1OC1=CC=C(F)C=C1 QLWNLVSIVRJGPY-XNWCZRBMSA-N 0.000 claims 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 claims 1
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 claims 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- 125000000586 2-(4-morpholinyl)ethoxy group Chemical group [H]C([H])(O*)C([H])([H])N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims 1
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 claims 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 claims 1
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 claims 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 claims 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims 1
- 206010053555 Arthritis bacterial Diseases 0.000 claims 1
- 206010003267 Arthritis reactive Diseases 0.000 claims 1
- 208000017925 Askin tumor Diseases 0.000 claims 1
- 108010024976 Asparaginase Proteins 0.000 claims 1
- 102000015790 Asparaginase Human genes 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 208000009766 Blau syndrome Diseases 0.000 claims 1
- UDKCHVLMFQVBAA-UHFFFAOYSA-M Choline salicylate Chemical compound C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O UDKCHVLMFQVBAA-UHFFFAOYSA-M 0.000 claims 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 108010092160 Dactinomycin Proteins 0.000 claims 1
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 claims 1
- 108010074604 Epoetin Alfa Proteins 0.000 claims 1
- 108010008165 Etanercept Proteins 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 201000003364 Extraskeletal myxoid chondrosarcoma Diseases 0.000 claims 1
- 108010069236 Goserelin Proteins 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 208000018565 Hemochromatosis Diseases 0.000 claims 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims 1
- 208000018208 Hyperimmunoglobulinemia D with periodic fever Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102100040018 Interferon alpha-2 Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 1
- 108010000817 Leuprolide Proteins 0.000 claims 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 claims 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims 1
- MQHWFIOJQSCFNM-UHFFFAOYSA-L Magnesium salicylate Chemical compound [Mg+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O MQHWFIOJQSCFNM-UHFFFAOYSA-L 0.000 claims 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- KTDZCOWXCWUPEO-UHFFFAOYSA-N NS-398 Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1CCCCC1 KTDZCOWXCWUPEO-UHFFFAOYSA-N 0.000 claims 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- 241001442654 Percnon planissimum Species 0.000 claims 1
- 206010073144 Peripheral primitive neuroectodermal tumour of soft tissue Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000006311 Pyoderma Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 claims 1
- 208000000389 T-cell leukemia Diseases 0.000 claims 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims 1
- JOOSFXXMIOXKAZ-UHFFFAOYSA-H [Au+3].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O Chemical compound [Au+3].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O JOOSFXXMIOXKAZ-UHFFFAOYSA-H 0.000 claims 1
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 claims 1
- 229960002184 abarelix Drugs 0.000 claims 1
- 108010023617 abarelix Proteins 0.000 claims 1
- 229960003697 abatacept Drugs 0.000 claims 1
- 229940022663 acetate Drugs 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 229960002478 aldosterone Drugs 0.000 claims 1
- 229960000548 alemtuzumab Drugs 0.000 claims 1
- 229960001445 alitretinoin Drugs 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims 1
- 229960003459 allopurinol Drugs 0.000 claims 1
- 229960000473 altretamine Drugs 0.000 claims 1
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 claims 1
- 229960001097 amifostine Drugs 0.000 claims 1
- 229960004238 anakinra Drugs 0.000 claims 1
- 229960002932 anastrozole Drugs 0.000 claims 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 230000002590 anti-leukotriene effect Effects 0.000 claims 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims 1
- 229960003272 asparaginase Drugs 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
- 229960002170 azathioprine Drugs 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 208000025255 bacterial arthritis Diseases 0.000 claims 1
- 229940092705 beclomethasone Drugs 0.000 claims 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 229940125388 beta agonist Drugs 0.000 claims 1
- 229960002537 betamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 229960003184 carprofen Drugs 0.000 claims 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 229960004630 chlorambucil Drugs 0.000 claims 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 1
- 229960002688 choline salicylate Drugs 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 208000002849 chondrocalcinosis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 229960002436 cladribine Drugs 0.000 claims 1
- 229960000928 clofarabine Drugs 0.000 claims 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 claims 1
- 229960003290 cortisone acetate Drugs 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 229960003901 dacarbazine Drugs 0.000 claims 1
- 229960000640 dactinomycin Drugs 0.000 claims 1
- 229960004486 desoxycorticosterone acetate Drugs 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960001259 diclofenac Drugs 0.000 claims 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 claims 1
- 229960000616 diflunisal Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- NYDXNILOWQXUOF-UHFFFAOYSA-L disodium;2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)NC(CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-UHFFFAOYSA-L 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 claims 1
- 229950004683 drostanolone propionate Drugs 0.000 claims 1
- 229960003388 epoetin alfa Drugs 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 229960001842 estramustine Drugs 0.000 claims 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 229960005293 etodolac Drugs 0.000 claims 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 claims 1
- 201000009593 extraosseous chondrosarcoma Diseases 0.000 claims 1
- 201000008815 extraosseous osteosarcoma Diseases 0.000 claims 1
- 229960001419 fenoprofen Drugs 0.000 claims 1
- VHUXSAWXWSTUOD-UHFFFAOYSA-L fenoprofen calcium (anhydrous) Chemical compound [Ca+2].[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1.[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 VHUXSAWXWSTUOD-UHFFFAOYSA-L 0.000 claims 1
- 230000003352 fibrogenic effect Effects 0.000 claims 1
- 206010016629 fibroma Diseases 0.000 claims 1
- 229960000556 fingolimod Drugs 0.000 claims 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
- 235000008191 folinic acid Nutrition 0.000 claims 1
- 239000011672 folinic acid Substances 0.000 claims 1
- 125000003838 furazanyl group Chemical group 0.000 claims 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 claims 1
- 229960005219 gentisic acid Drugs 0.000 claims 1
- 229960003690 goserelin acetate Drugs 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 claims 1
- 229960003911 histrelin acetate Drugs 0.000 claims 1
- BKEMVGVBBDMHKL-VYFXDUNUSA-N histrelin acetate Chemical compound CC(O)=O.CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 BKEMVGVBBDMHKL-VYFXDUNUSA-N 0.000 claims 1
- 229960001330 hydroxycarbamide Drugs 0.000 claims 1
- 229960004171 hydroxychloroquine Drugs 0.000 claims 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 229960000908 idarubicin Drugs 0.000 claims 1
- 229960001101 ifosfamide Drugs 0.000 claims 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
- 229960003685 imatinib mesylate Drugs 0.000 claims 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 229960000905 indomethacin Drugs 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 229960004752 ketorolac Drugs 0.000 claims 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims 1
- 229960004384 ketorolac tromethamine Drugs 0.000 claims 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 claims 1
- 150000002596 lactones Chemical class 0.000 claims 1
- 229960000681 leflunomide Drugs 0.000 claims 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 1
- 229960003881 letrozole Drugs 0.000 claims 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 1
- 229960001691 leucovorin Drugs 0.000 claims 1
- 206010024378 leukocytosis Diseases 0.000 claims 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims 1
- 229960004338 leuprorelin Drugs 0.000 claims 1
- 229960001614 levamisole Drugs 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 229960002247 lomustine Drugs 0.000 claims 1
- 229960000994 lumiracoxib Drugs 0.000 claims 1
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000012804 lymphangiosarcoma Diseases 0.000 claims 1
- 229940072082 magnesium salicylate Drugs 0.000 claims 1
- 229960004961 mechlorethamine Drugs 0.000 claims 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 229960003464 mefenamic acid Drugs 0.000 claims 1
- 229960004296 megestrol acetate Drugs 0.000 claims 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims 1
- 229960001929 meloxicam Drugs 0.000 claims 1
- 229960001924 melphalan Drugs 0.000 claims 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 1
- 229960000901 mepacrine Drugs 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229960004584 methylprednisolone Drugs 0.000 claims 1
- 206010072221 mevalonate kinase deficiency Diseases 0.000 claims 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims 1
- 229960004023 minocycline Drugs 0.000 claims 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 claims 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims 1
- 229960001156 mitoxantrone Drugs 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims 1
- 229960000951 mycophenolic acid Drugs 0.000 claims 1
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 claims 1
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 claims 1
- SSRSGTALZFPLPI-RMKNXTFCSA-N n-[4-(3-chlorophenoxy)-3-[(e)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]pyridine-3-carboxamide Chemical compound C=1C=C(OC=2C=C(Cl)C=CC=2)C(/C=C/C(=O)NO)=CC=1NC(=O)C1=CC=CN=C1 SSRSGTALZFPLPI-RMKNXTFCSA-N 0.000 claims 1
- BWWOCIUEWURNHG-RMKNXTFCSA-N n-[4-(3-fluorophenoxy)-3-[(e)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]pyridine-3-carboxamide Chemical compound C=1C=C(OC=2C=C(F)C=CC=2)C(/C=C/C(=O)NO)=CC=1NC(=O)C1=CC=CN=C1 BWWOCIUEWURNHG-RMKNXTFCSA-N 0.000 claims 1
- HDUWKQUHMUSICC-UHFFFAOYSA-N n-[6-(2,4-difluorophenyl)sulfanyl-1-oxo-2,3-dihydroinden-5-yl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2CCC(=O)C=2C=C1SC1=CC=C(F)C=C1F HDUWKQUHMUSICC-UHFFFAOYSA-N 0.000 claims 1
- 229960004270 nabumetone Drugs 0.000 claims 1
- 229960004719 nandrolone Drugs 0.000 claims 1
- NPAGDVCDWIYMMC-IZPLOLCNSA-N nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 230000002956 necrotizing effect Effects 0.000 claims 1
- 229960003966 nicotinamide Drugs 0.000 claims 1
- 235000005152 nicotinamide Nutrition 0.000 claims 1
- 239000011570 nicotinamide Substances 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960002739 oxaprozin Drugs 0.000 claims 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- GTUJJVSZIHQLHA-XPWFQUROSA-N pApA Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@@H]1O)O[C@H](COP(O)(O)=O)[C@H]1OP(O)(=O)OC[C@H]([C@@H](O)[C@H]1O)O[C@H]1N1C(N=CN=C2N)=C2N=C1 GTUJJVSZIHQLHA-XPWFQUROSA-N 0.000 claims 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims 1
- 229940046231 pamidronate Drugs 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 claims 1
- 229960001218 pegademase Drugs 0.000 claims 1
- 108010027841 pegademase bovine Proteins 0.000 claims 1
- 229960001744 pegaspargase Drugs 0.000 claims 1
- 108010001564 pegaspargase Proteins 0.000 claims 1
- 229960001373 pegfilgrastim Drugs 0.000 claims 1
- 108010044644 pegfilgrastim Proteins 0.000 claims 1
- 229960003349 pemetrexed disodium Drugs 0.000 claims 1
- 229960002340 pentostatin Drugs 0.000 claims 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 208000025487 periodic fever syndrome Diseases 0.000 claims 1
- 210000004786 perivascular cell Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims 1
- 229960002702 piroxicam Drugs 0.000 claims 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 1
- 229960003171 plicamycin Drugs 0.000 claims 1
- 229960004293 porfimer sodium Drugs 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims 1
- 229960000624 procarbazine Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 claims 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 229960004025 sodium salicylate Drugs 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- 229960001052 streptozocin Drugs 0.000 claims 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229960001940 sulfasalazine Drugs 0.000 claims 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 1
- 229960000894 sulindac Drugs 0.000 claims 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims 1
- 229960002812 sunitinib malate Drugs 0.000 claims 1
- 206010042863 synovial sarcoma Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 229960001967 tacrolimus Drugs 0.000 claims 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
- 229960004964 temozolomide Drugs 0.000 claims 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims 1
- 229960001278 teniposide Drugs 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 229960003433 thalidomide Drugs 0.000 claims 1
- 229960000278 theophylline Drugs 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 229960001196 thiotepa Drugs 0.000 claims 1
- MIMJSJSRRDZIPW-UHFFFAOYSA-N tilmacoxib Chemical compound C=1C=C(S(N)(=O)=O)C(F)=CC=1C=1OC(C)=NC=1C1CCCCC1 MIMJSJSRRDZIPW-UHFFFAOYSA-N 0.000 claims 1
- 229960003087 tioguanine Drugs 0.000 claims 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- 229960005294 triamcinolone Drugs 0.000 claims 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 229960002004 valdecoxib Drugs 0.000 claims 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 claims 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 1
- 229960000237 vorinostat Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161581459P | 2011-12-29 | 2011-12-29 | |
| US61/581,459 | 2011-12-29 | ||
| PCT/US2012/070671 WO2013101600A1 (en) | 2011-12-29 | 2012-12-19 | Cinnamic acid hydroxyamides as inhibitors of histone deacetylase 8 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015504056A JP2015504056A (ja) | 2015-02-05 |
| JP2015504056A5 true JP2015504056A5 (enExample) | 2016-02-12 |
Family
ID=48698536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014550354A Pending JP2015504056A (ja) | 2011-12-29 | 2012-12-19 | ヒストンデアセチラーゼ８の阻害剤としての珪皮酸ヒドロキシアミド |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20150045367A1 (enExample) |
| EP (1) | EP2797875A4 (enExample) |
| JP (1) | JP2015504056A (enExample) |
| CN (1) | CN104136410A (enExample) |
| AU (1) | AU2012362726A1 (enExample) |
| CA (1) | CA2862259A1 (enExample) |
| HK (1) | HK1200809A1 (enExample) |
| MX (1) | MX2014007969A (enExample) |
| WO (1) | WO2013101600A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105979941A (zh) * | 2013-08-20 | 2016-09-28 | 希望之城 | 用于治疗癌症的hdac8抑制剂 |
| EP3932914A1 (en) | 2015-03-13 | 2022-01-05 | Valo Health, Inc. | Alpha-cinnamide compounds and compositions as hdac8 inhibitors |
| CN104788391B (zh) * | 2015-04-21 | 2017-03-08 | 中国医学科学院医药生物技术研究所 | 肉桂酰中性红酰胺(ca‑pz)及其制备与应用 |
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| US11491146B2 (en) * | 2017-06-23 | 2022-11-08 | Yuk Yin Sham | Therapeutic methods and combinations |
| WO2020061117A1 (en) * | 2018-09-18 | 2020-03-26 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| WO2021021979A2 (en) | 2019-07-30 | 2021-02-04 | Eikonizo Therapapeutics, Inc. | Hdac6 inhibitors and uses thereof |
| CA3152297A1 (en) * | 2019-11-06 | 2021-05-14 | Eric S. FISCHER | Selective dual histone deacetylase 6/8 (hdac6/8) degraders and methods of use thereof |
| CN111068055A (zh) * | 2019-12-11 | 2020-04-28 | 上海交通大学医学院附属瑞金医院 | 一种联合抑制剂及其应用 |
| JP7828089B2 (ja) * | 2020-07-08 | 2026-03-11 | クロトー セラピューティクス インコーポレイテッド | Ｈｄａｃ阻害及び急性腎障害後の腎臓回復の促進に使用するためのｐｔｂａの水溶性プロドラッグ |
| CN116261456B (zh) * | 2020-08-14 | 2025-07-08 | 戴纳立制药公司 | 化合物、组合物和方法 |
| US12377086B2 (en) | 2021-05-27 | 2025-08-05 | Yuk Yin Sham | Therapeutic methods, combinations and kits |
| JP7742660B2 (ja) * | 2021-05-28 | 2025-09-22 | ノーベルワイズ・ファーマシューティカル・コーポレイション | 薬物耐性癌を処置するための組成物および方法 |
| EP4504190A4 (en) | 2022-04-08 | 2026-03-25 | Eikonizo Therapeutics Inc | OXADIAZOLE HDAC6 INHIBITORS AND THEIR USES |
| CN118638077B (zh) * | 2024-06-04 | 2025-06-27 | 杭州师范大学 | 酰胺/磺酰胺类cxcr4/hdac双重抑制剂及其制备方法和应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4717889A (en) * | 1988-12-29 | 1990-07-05 | Ciba-Geigy Ag | Amino-substituted hydroxamic acids |
| EP0570594B1 (en) * | 1991-12-10 | 1997-07-30 | Shionogi & Co., Ltd. | Hydroxamic acid derivative based on aromatic sulfonamide |
| JPH07278086A (ja) * | 1993-11-08 | 1995-10-24 | Terumo Corp | ヒドロキサム酸誘導体およびそれを含有する医薬製剤 |
| JPH10182583A (ja) * | 1996-12-25 | 1998-07-07 | Mitsui Chem Inc | 新規ヒドロキサム酸誘導体 |
| PE20020354A1 (es) * | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| JP4975941B2 (ja) * | 2000-09-29 | 2012-07-11 | トポターゲット ユーケー リミテッド | （ｅ）−ｎ−ヒドロキシ−３−（３−スルファモイル−フェニル）アクリルアミド化合物及びその治療用途 |
| BR0308908A (pt) * | 2002-04-03 | 2005-01-04 | Topotarget Uk Ltd | Composto, composição, uso de um composto, e, métodos para inibir a hdac em uma célula, para o tratamento de uma condição mediada pela hdac, de um condição proliferativa, de câncer e de psorìase |
| TW200418806A (en) * | 2003-01-13 | 2004-10-01 | Fujisawa Pharmaceutical Co | HDAC inhibitor |
| AU2003900587A0 (en) * | 2003-02-11 | 2003-02-27 | Fujisawa Pharmaceutical Co., Ltd. | Hdac inhibitor |
| JP2004277311A (ja) * | 2003-03-14 | 2004-10-07 | Wakunaga Pharmaceut Co Ltd | 新規ｍｍｐ−３阻害剤 |
| KR20050122210A (ko) * | 2003-03-17 | 2005-12-28 | 다케다 샌디에고, 인코포레이티드 | 히스톤 탈아세틸화 효소 억제제 |
| US20070167499A1 (en) * | 2003-10-27 | 2007-07-19 | A*Bio Pte Ltd. | Biaryl linked hydroxamates: preparation and pharmaceutical applications |
| ITMI20040876A1 (it) * | 2004-04-30 | 2004-07-30 | Univ Degli Studi Milano | Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari |
| EP1771167A4 (en) * | 2004-07-19 | 2010-04-21 | Merck Sharp & Dohme | Histone deacetylase INHIBITORS: |
| ITMI20041869A1 (it) * | 2004-10-01 | 2005-01-01 | Dac Srl | Nuovi inibitori delle istone deacetilasi |
| CN102579417B (zh) * | 2005-05-13 | 2014-11-26 | 托波塔吉特英国有限公司 | Hdac抑制剂的药物制剂 |
| PL1896399T3 (pl) * | 2005-06-28 | 2011-04-29 | Sigma Tau Ind Farmaceuti | Bifenylowe i naftylo-fenylowe pochodne kwasu hydroksyamowego |
| PT1928872E (pt) * | 2005-09-21 | 2012-05-25 | 4Sc Ag | Utilização de novos sulfonilpirroles como inibidores de hdacs |
| EP2049483A2 (en) * | 2006-10-28 | 2009-04-22 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| MX2009006542A (es) * | 2006-12-19 | 2009-06-30 | Methylgene Inc | Inhibidores de histona desacetilasa y sus profarmacos. |
| KR20100074288A (ko) * | 2007-10-22 | 2010-07-01 | 오키드 리서치 레버라토리즈 리미티드 | 히스톤 디아세틸라제 억제제 |
| CN101417967A (zh) * | 2007-10-26 | 2009-04-29 | 浙江海正药业股份有限公司 | 组蛋白去乙酰酶抑制剂、其组合物及其应用 |
| PT2260020E (pt) * | 2008-03-26 | 2014-10-28 | Novartis Ag | Inibidores das desacetilases b baseados no hidroxamato |
| GB0903480D0 (en) * | 2009-02-27 | 2009-04-08 | Chroma Therapeutics Ltd | Enzyme Inhibitors |
| US7994357B2 (en) * | 2009-04-03 | 2011-08-09 | Naturewise Biotech & Medicals Corporation | Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase |
| CN102548975A (zh) * | 2009-07-07 | 2012-07-04 | 安瑟生物科技私人有限公司 | 组蛋白去乙酰化酶抑制剂 |
| EP2277387B1 (en) * | 2009-07-22 | 2016-10-19 | NatureWise Biotech & Medicals Corporation | New use of histone deacetylase inhibitors in changing mrjp3 protein in royal jelly |
| US8716344B2 (en) * | 2009-08-11 | 2014-05-06 | President And Fellows Of Harvard College | Class- and isoform-specific HDAC inhibitors and uses thereof |
| US20110060009A1 (en) * | 2009-08-28 | 2011-03-10 | Novartis Ag | Hydroxamate-Based Inhibitors of Deacetylases |
| US20130040998A1 (en) * | 2010-01-08 | 2013-02-14 | Dana-Farber Cancer Institute, Inc. | Fluorinated hdac inhibitors and uses thereof |
| US9260382B2 (en) * | 2010-02-16 | 2016-02-16 | Uwm Research Foundation | Methods of reducing virulence in bacteria |
-
2012
- 2012-12-19 WO PCT/US2012/070671 patent/WO2013101600A1/en not_active Ceased
- 2012-12-19 CN CN201280070962.3A patent/CN104136410A/zh active Pending
- 2012-12-19 JP JP2014550354A patent/JP2015504056A/ja active Pending
- 2012-12-19 HK HK15101461.1A patent/HK1200809A1/xx unknown
- 2012-12-19 US US14/368,475 patent/US20150045367A1/en not_active Abandoned
- 2012-12-19 AU AU2012362726A patent/AU2012362726A1/en not_active Abandoned
- 2012-12-19 EP EP12863933.3A patent/EP2797875A4/en not_active Withdrawn
- 2012-12-19 CA CA2862259A patent/CA2862259A1/en not_active Abandoned
- 2012-12-19 MX MX2014007969A patent/MX2014007969A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3026359T3 (en) | Ccx168 for use in the treatment of c3 glomerulopathy | |
| ES2425739T3 (es) | Sorafenib-tosilato para el tratamiento de enfermedades caracterizadas por angiogénesis anormal | |
| JP2021530523A (ja) | Ｈｉｖの処置のためのカプシド阻害剤 | |
| BR112018071678B1 (pt) | compostos terapêuticos úteis para o tratamento profilático ou terapêutico de uma infecção por vírus hiv e suas composições farmacêuticas | |
| RU2765737C2 (ru) | Способ лечения фокально-сегментарного гломерулосклероза | |
| JP2022529370A5 (enExample) | ||
| JP2014500295A5 (enExample) | ||
| CA3053818A1 (en) | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | |
| AU2017274521A1 (en) | Method of treating liver fibrosis | |
| TWI913215B (zh) | 減少尿液sCD163之C5aR抑制劑 | |
| RU2015124002A (ru) | Соединения, применяемые в качестве ингибиторов индоламин-2,3-диоксигеназы | |
| RU2011121567A (ru) | Изоиндолиновые соединения для применения при лечении рака | |
| US20200306255A1 (en) | Compositions and methods for treating niemann pick c disease | |
| JP2018529780A5 (enExample) | ||
| EP3204424A1 (en) | Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies | |
| JP7806119B2 (ja) | 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用 | |
| JP2026053473A (ja) | 癌または炎症性疾患の治療のためのヘテロ二環式カルボキシ酸 | |
| JP2018529737A5 (enExample) | ||
| JP2016507500A5 (enExample) | ||
| EP1948170A1 (en) | Diaryl urea for treating pulmonary hypertension | |
| JP7323631B2 (ja) | 疼痛の治療のためのｇａｂａａ受容体モジュレーターの使用 | |
| ES2363056T3 (es) | Utilización de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-óxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos de la médula espinal. | |
| JP2022552975A (ja) | 関節リウマチを予防及び／又は治療するためのニコチンアミドモノヌクレオチド（ｎｍｎ）の使用、並びに対応する組成物 | |
| JP6433980B2 (ja) | Ｎｓａｉｄ投与並びに関連する組成物、方法及びシステム | |
| JP7787823B2 (ja) | Ｃｃｒ９阻害剤及び抗ｉｌ－２３遮断抗体を使用する炎症性腸疾患を治療するための組成物及び方法 |